Risk factors for mortality after linezolid treatment of vancomycin-resistant Enterococcus bloodstream infection

Risk factors for mortality after linezolid treatment of vancomycin-resistant Enterococcus bloodstream infection

Objectives: We analyzed the risk factors affecting linezolid treatment outcome in vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI). Methods: We conducted a multicenter observational study of patients who received linezolid 600 mg every 12 hours for VRE BSI. The primary outcome was...

Full description

Bibliographic Details
Main Authors: Szu-Ting Huang, Jia-Ling Yang, Chi-Ying Lin, Sung-Hsi Huang, Jann-Tay Wang, Yu-Chung Chuang, Yee-Chun Chen, Shan-Chwen Chang
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:International Journal of Infectious Diseases
Subjects:
Linezolid
Pharmacodynamic
Mortality
Vancomycin-resistant enterococci
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971223000358

Internet

http://www.sciencedirect.com/science/article/pii/S1201971223000358

Similar Items